Novartis is discontinuing the development of GT005 for the treatment of geographic atrophy secondary to dry age-related macular degeneration, according to a press release from Syncona.
The decision by Novartis to stop the development of the AAV2-based gene therapy was based on a recommendation from an independent data monitoring committee “following an overall benefit-risk assessment of available data from the [program] studies, which concluded that overall data from the lead phase 2 HORIZON study did not support continuation of the development [program],” the release said.
Novartis